{"entity":{"id":"nct06888921","kind":"trial","name":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","aka":[],"tldr":"A phase 1/2 trial of COM701 in ovarian cancer, run by Compugen Ltd, now recruiting.","summary":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer is a phase 1/2 interventional study registered as NCT06888921 by Compugen Ltd, with 60 participants planned, started 2025-07-21 and due to reach its primary completion in 2027-03. Interventions recorded: COM701 and Normal Saline.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06888921","url":"https://clinicaltrials.gov/study/NCT06888921"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-sensitive-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06888921","phase":"1/2","setting":"An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)","sponsor":"Compugen Ltd","started":"2025-07-21","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06888921/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/"}],"company":[{"id":"compugen","kind":"company","name":"Compugen","route":"/companies/compugen/"}]}}